Advertisement
Mayo Clinic Proceedings Home

Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999–2018

      Abstract

      Approval by the US Food and Drug Administration (FDA) of a drug for a given indication is thought to reassure clinicians, other health care providers, and patients that substantial evidence of effectiveness exists for specific indicated populations (patients and diseases). This study examines whether FDA approval of certain antibiotics should be so reassuring for all patient populations identified in the FDA-approved labels. Specifically, this study compared patient populations covered by FDA-approved labels for 21 novel antibiotics approved between 1999 and 2018 to the patient exclusion and inclusion criteria of pivotal trials that supported those approvals. We found that every FDA-approved label for these antibiotics included at least one identifiable patient population that was explicitly excluded from enrolling in the supporting pivotal trials. Two antibiotics, bedaquiline and ceftazidime-avibactam, were approved for use in populations that were fully excluded from enrolling in registration trials.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Eguale T.
        • Buckeridge D.L.
        • Verma A.
        • et al.
        Association of off-label drug use and adverse drug events in an adult population.
        JAMA Intern Med. 2016; 176: 55-63
        • Olbrisch K.
        • Kisch T.
        • Thern J.
        • et al.
        After standard dosage of piperacillin plasma concentrations of drug are subtherapeutic in burn patients.
        Naunyn Schmiedebergs Arch Pharmacol. 2019; 392: 229-241
        • Food and Drug Administration
        FDA approves new antibacterial drug Avycaz [Internet]. 2015.
        • Food and Drug Administration
        [email protected]: FDA Approved Drug Products [Internet]. 2017.
        https://www.fda.gov/drugsatfda
        Date accessed: April 20, 2017
        • Kuzucan A.
        • Powers J.
        • Onwuchekwa Uba R.
        • Doshi P.
        Dataset for Kuzucan et al. Approvals for use in populations specifically excluded from trials supporting FDA-approved antibiotics, 1999-2018. [Internet]. 2019.
        https://doi.org/10.5281/zenodo.3265478
        Date accessed: May 7, 2020
        • Safdar N.
        • Maki D.G.
        The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida.
        Ann Intern Med. 2002; 136: 834-844
        • Rex J.H.
        • Talbot G.H.
        • Goldberger M.J.
        • et al.
        Progress in the fight against multidrug-resistant bacteria 2005-2016: modern noninferiority trial designs enable antibiotic development in advance of epidemic bacterial resistance.
        Clin Infect Dis. 2017; 65: 141-146
        • Fleming T.R.
        • Powers J.H.
        Issues in noninferiority trials: the evidence in community-acquired pneumonia.
        Clin Infect Dis. 2008; 47: S108-S120
        • Prasad P.
        • Sun J.
        • Danner R.L.
        • Natanson C.
        Excess deaths associated with tigecycline after approval based on noninferiority trials.
        Clin Infect Dis. 2012; 54: 1699-1709
        • Powers J.H.
        • Evans S.R.
        • Kesselheim A.S.
        Studying new antibiotics for multidrug resistant infections: are today’s patients paying for unproved future benefits?.
        BMJ. 2018; 360: k587
        • Deak D.
        • Outterson K.
        • Powers J.H.
        • Kesselheim A.S.
        Progress in the fight against multidrug-resistant bacteria? A review of U.S. Food and Drug Administration–approved antibiotics, 2010–2015.
        Ann Intern Med. 2016; 165: 363-372
        • Food and Drug Administration
        Limited Population Pathway for Antibacterial and Antifungal Drugs: Guidance for Industry [Internet]. 2018.
        https://www.fda.gov/media/113729/download
        Date accessed: November 20, 2019
      1. 21st Century Cures Act [Internet]. 114–255 Dec 13, 2016 p. 312.